Navigation Links
Neurobiological Technologies, Inc. (Nasdaq: NTII) Q2/08 Review Issued By Scimitar Equity Research, Inc.
Date:2/14/2008

BOSTON, Feb. 14 /PRNewswire/ -- Scimitar Equity Research, Inc. (Scimitar) issues a review of Neurobiological Technologies, Inc. (Nasdaq: NTII), entitled, "When You Review Stroke Treatments, Look at One Stroke Drug at a Time; Each One is Different".

This review is available at our website: http://www.scimitarequity.com.

Neurobiological Technologies, Inc. (NTII) is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. NTII is a specialty biopharmaceutical company with expertise in identifying and acquiring promising drug candidates and in designing and managing late-stage clinical trials for central nervous system conditions. Neurobiological Technologies, Inc is currently developing Viprinex(TM) (ancrod), a novel reperfusion agent that is in pivotal Phase 3 trials for the treatment of acute ischemic stroke. For further information, please visit NTII's website at http://www.ntii.com.

Scimitar Equity Research, Inc provides sponsored equity research of emerging healthcare companies for the investing communities. We certify that all the views expressed in this review, accurately reflect our personal views about NTII (NASDAQ) and its or their securities. No part of our compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views contained in this review and we will not have any investment banking relationships or personal investment in any sponsored company. Investors are advised that this analysis and review is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy. Scimitar was paid for preparing this review. This analysis and review does not have regard to the specific investment objectives, financial situation and the information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Any opinions expressed are statements of our own judgment as of the date of publication and are subject to change without notice. Please read all our important disclosures.

CONTACT:

Scimitar Equity Research, Inc.

Henry W. McCusker

Director of Research

phone: (617) 559.1080

fax: (617) 559.1083

e-mail: hwm@scimitarequity.com


'/>"/>
SOURCE Scimitar Equity Research, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
2. Neurobiological Technologies Sets Date for Second Quarter Financial Results
3. Neurobiological Technologies, Inc. Reports Retirement of Ronald E. Cape, Ph.D., from Board
4. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q1/08 Review Issued By Scimitar Equity Research, Inc.
5. Neurobiological Technologies Announces Pricing of Its $60 Million Common Stock Offering
6. Neurobiological Technologies, Inc. (Nasdaq: NTIID)
7. Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
8. Neurobiological Technologies, Inc. Reports Receipt of Notice From Nasdaq
9. Genelabs Technologies, Inc. Announces Resignation of President and CEO
10. GSA Selects Cascades Technologies, Inc. (CTi) to Support USA.gov
11. Healthcare Technologies, Ltd. Receives Notice From Nasdaq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... Charm Sciences, Inc. is pleased to ... was determined to be appropriate as a screening test at dairies and farms for ... EZ system, and the Charm EZ Lite system. These systems are a combination incubator ...
(Date:6/20/2017)... ... June 20, 2017 , ... Biologist Dawn Maslar MS has found a biomarker ... Men Chase, Women Choose: The Neuroscience of Meeting, Dating, Losing Your Mind, and Finding ... men. ”The logical next step, in my estimation, was to scientifically track the evidence ...
(Date:6/20/2017)... , June 20, 2017  Kibow Biotech Inc., ... to announce the issuance of a new patent covering ... hyperuricemia by the U.S. Patent and Trademark Office on ... winner of the Buzz of Bio award in 2014 ... akin to developing non-drug approaches to chronic disease. Renadyl™, ...
(Date:6/20/2017)... NJ (PRWEB) , ... June 20, 2017 , ... Do ... makes the transition from being a trusted supplier in the weighing industry, to extending ... cell extractions, ELISA essays, enzyme reactions, immunoassays, hybridizations and more, allowing for its ...
Breaking Biology Technology:
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/24/2017)... 2017 Janice Kephart , former ... Strategy Partners, LLP (IdSP) , today issues the ... Trump,s March 6, 2017 Executive Order: Protecting ... can be instilled with greater confidence, enabling the ... refugee applications are suspended by until at least ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
Breaking Biology News(10 mins):